Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hepatitis b virus vaccine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant hepatitis B virus vaccine is a subunit vaccine containing the hepatitis B surface antigen (HBsAg), produced via recombinant DNA technology typically in yeast cells (*Saccharomyces cerevisiae*). It is designed to prevent infection by the hepatitis B virus (HBV) by inducing the production of neutralizing anti-HBs antibodies. The Universidad de Valparaiso has sponsored Phase 3 clinical research, specifically the CORE-HIV trial (NCT01552629), to evaluate the efficacy of intensified re-vaccination schedules in HIV-infected patients who previously failed to respond to standard vaccination. This research compared a high-dose (40 mcg) re-vaccination regimen against a standard-dose (20 mcg) regimen to optimize seroprotection rates in this immunocompromised population.
- Other names
- recombinant hepatitis B vaccineHBV vaccineHepatitis B vaccine (recombinant)
02
Targets
HBsAg (Hepatitis B surface antigen)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))NTCP (Na+-taurocholate cotransporting polypeptide)
Beyond the preview
Go deeper on recombinant hepatitis b virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hepatitis b virus vaccine.